Myeloma as a second malignancy following AML: Is a second allo equivalent to auto?

Creative Commons License

Bakanay S. M., Serbest E., DALVA K., KUZU I., BEKSAÇ M.

Case Reports in Medicine, vol.2012, 2012 (SCI-Expanded) identifier

  • Publication Type: Article / Article
  • Volume: 2012
  • Publication Date: 2012
  • Doi Number: 10.1155/2012/319530
  • Journal Name: Case Reports in Medicine
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Ankara University Affiliated: Yes

Abstract

We report a young male patient who developed plasma cell myeloma/plasmacytoma 11 years after having received an allogeneic hematopoietic cell transplantation for AML. The patient received a second transplantation from the same donor without immunosuppression and developed graft-versus-host disease (GVHD). Our observation has two aspects that warrant attention: first, insufficiency of long-term tolerance to prevent GVHD in the absence of immunosuppression and second, a stromal or genetic susceptibility to develop hematologic malignancies despite of a complete donor-type chimerism. Copyright © 2012 Sule Mine Bakanay et al.